
    
      The study is a prospective, randomized, four-arm, dose-escalating, double blind, placebo
      controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of four dose
      levels of MTR105 in patients undergoing cardiac surgery utilizing cardiopulmonary bypass
      presenting hypotension upon weaning off bypass.
    
  